The Shuman Law Firm Investigates Salix Pharmaceuticals Ltd.

BOULDER, Colo.--()--The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Salix Pharmaceuticals Ltd. (“Salix” or the “Company”) (Nasdaq: SLXP). Salix is a Raleigh, NC-based company develops and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases.

The Firm’s investigation relates to the Company’s November 6, 2014 disclosure that its Chief Financial Officer had resigned, its wholesaler inventory levels were three times greater than previously reported, and that its previously-issued guidance for full-year 2014 revenues would not be met and would be drastically reduced. Following this disclosure, Salix’s common stock fell declined more than 38%, or $53.05 per share, during after-hours trading on November 6, 2014, to $85.50 per share, on unusually heavy volume. Salix’s stock price has yet to fully recover, and currently trades around $119 per share.

If you currently own Salix common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at (866) 569-4531or email Mr. Shuman at or email Mr. Glenn at

The Shuman Law Firm represents investors throughout the nation, concentrating its practice in stockholder litigation.


The Shuman Law Firm
Kip B. Shuman, Esq., 303-861-3003
Rusty E. Glenn, Esq., 303-861-3003
Toll-Free: 866-569-4531
Fax: 303-536-7849

Recent Stories

RSS feed for The Shuman Law Firm


Release Summary

The Shuman Law Firm investigates Salix Pharmaceuticals Ltd. (Nasdaq: SLXP).

The Shuman Law Firm